ONWARD Medical Raises €40 Million in Capital Increase Led by EQT Life Sciences for Spinal Cord Stimulation Technology

Key Takeaways

• ONWARD Medical launches €40 million capital increase through private placement with major participation from EQT Life Sciences investing €25 million
• Funding will accelerate development of innovative spinal cord stimulation technologies for treating paralysis and movement disorders
• Investment validates ONWARD’s pioneering approach to restoring movement and improving quality of life for patients with spinal cord injuries

---

ONWARD Medical Secures Major Investment for Spinal Cord Innovation

ONWARD Medical, a leading medical technology company developing spinal cord stimulation therapies, announced a significant €40 million capital increase through a private placement. The funding round features substantial participation from EQT Life Sciences, which is expected to contribute €25 million to the investment.

Strategic Partnership with EQT Life Sciences

The partnership with EQT Life Sciences represents a major validation of ONWARD Medical’s innovative approach to treating spinal cord injuries and movement disorders. EQT Life Sciences, known for backing breakthrough healthcare technologies, brings both capital and strategic expertise to support ONWARD’s mission of restoring movement for patients with paralysis.

Advancing Spinal Cord Stimulation Technology

ONWARD Medical specializes in developing precision neurostimulation therapies that target the spinal cord to restore movement and improve quality of life for patients with spinal cord injuries. The company’s technology platform focuses on delivering targeted electrical stimulation to specific neural circuits, potentially enabling patients to regain motor function.

Market Impact and Future Outlook

This significant funding injection positions ONWARD Medical to accelerate clinical development programs and expand its research capabilities. The medical device sector for neurological disorders represents a growing market, with increasing demand for innovative solutions that can provide meaningful improvements in patient outcomes.

The investment comes at a crucial time as the company advances its clinical pipeline and works toward regulatory approvals for its spinal cord stimulation technologies. With EQT Life Sciences’ backing, ONWARD Medical is well-positioned to continue its pioneering work in the neurostimulation field.

Investment Structure and Timeline

Stifel Europe Securities is managing the private placement, ensuring proper execution of the capital increase. The funding will support ongoing clinical trials, product development, and potential market expansion activities as ONWARD Medical progresses toward commercialization of its innovative therapies.

---

Frequently Asked Questions

What will ONWARD Medical use the €40 million funding for?

The funding will accelerate development of spinal cord stimulation technologies, support clinical trials, and advance the company’s neurostimulation platform for treating paralysis and movement disorders.

Who is EQT Life Sciences and why is their investment significant?

EQT Life Sciences is a prominent healthcare investment firm known for backing breakthrough medical technologies. Their €25 million investment validates ONWARD’s approach and provides strategic expertise alongside capital.

How does ONWARD Medical’s technology help patients with spinal cord injuries?

ONWARD’s precision neurostimulation technology delivers targeted electrical stimulation to specific spinal cord circuits, potentially enabling patients with paralysis to regain motor function and improve quality of life.